Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

Identify the Recommended Phase 2 Dose (RP2D) (Part A)

The RP2D was to be determined after the maximum tolerated dose was reached in Part A.

Time frame: Day 1 up to 12 months

Change in Viral Load Cycle Threshold From Baseline to Day 28 (Part A)

Viral load was measured by quantitative polymerase chain reaction (PCR) of nasal swab specimens. The cycle threshold value categorizes the concentration of viral genetic material in a participant's swab specimen, and the cycle threshold value represents the number of PCR cycles required to amplify the viral genetic material (as measured by fluorescence) to a detectable level that is distinguishable from baseline fluorescence, providing an estimate of viral load. Lower cycle threshold values indicate higher viral load and high values indicate lower viral load. A positive change from baseline indicates a decrease in the viral load. The baseline measurement was from a pre-dose nasal swab.

Time frame: Baseline and Day 28

Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Part B)

Time frame: Day 1 up to 12 months

Percentage Reduction in Viral Load From Baseline to Month 6 (Part B)

Time frame: Day 1 and Month 6